Altamira Therapeutics (Altamira Therapeutics) Total Liabilities : $1.43 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Altamira Therapeutics Total Liabilities?

Altamira Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 was $1.43 Mil.

Altamira Therapeutics's quarterly Total Liabilities declined from Dec. 2022 ($15.69 Mil) to Jun. 2023 ($8.92 Mil) and declined from Jun. 2023 ($8.92 Mil) to Dec. 2023 ($1.43 Mil).

Altamira Therapeutics's annual Total Liabilities increased from Dec. 2021 ($6.66 Mil) to Dec. 2022 ($15.69 Mil) but then declined from Dec. 2022 ($15.69 Mil) to Dec. 2023 ($1.43 Mil).

Altamira Therapeutics Total Liabilities Historical Data

The historical data trend for Altamira Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics Total Liabilities Chart

Altamira Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3.25

4.54

6.66

15.69

1.43

Altamira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Liabilities	Get a 7-Day Free Trial															6.66	11.14	15.69	8.92	1.43

Altamira Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Altamira Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.028	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.401)
	=	1.43

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	8.897	-	7.469
	=	1.43

Altamira Therapeutics's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.028	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0.401)
	=	1.43

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	8.897	-	7.469
	=	1.43

Altamira Therapeutics Total Liabilities Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Altamira Therapeutics (Altamira Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (NAS:CYTO) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.altamiratherapeutics.com

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens.